Literature DB >> 7870969

Discriminative stimulus effects of omega (BZ) receptor ligands: correlation with in vivo inhibition of [3H]-flumazenil binding in different regions of the rat central nervous system.

D J Sanger1, J Benavides.   

Abstract

Rats can be trained to discriminate benzodiazepines (BZ) from vehicle and there is considerable evidence that the stimulus effects of these drugs are mediated by activity at omega (BZ) modulatory sites of the GABAA receptor complex. A number of recent studies, however, have indicated that differences may exist between the discriminative stimulus effects of benzodiazepines and those of certain non-benzodiazepine ligands for the omega (BZ) receptors (e.g. zolpidem, abecarnil). As it is known that several subtypes of omega (BZ) sites are found in the central nervous system, and that drugs such as zolpidem have selectivity for certain subtypes, it is possible that differential stimulus effects may be associated with receptor selectivity. In the present study, correlations were calculated between the potencies of nine compounds with affinity for omega receptors (diazepam, lorazepam, triazolam, clonazepam, alprazolam, zopiclone, suriclone, CL 218, 872 and zolpidem) to substitute for chlordiazepoxide in rats trained to discriminate a dose (5 mg/kg) of this benzodiazepine and the ability of the same compounds to inhibit the binding of [3H]-flumazenil from different structures in the rat central nervous system in vivo. The correlations obtained were: cerebellum 0.46, cortex 0.39, striatum 0.78 (P < 0.05), hippocampus 0.79 (P < 0.05) and spinal cord 0.95 (P < 0.001). These different structures are known to contain different relative concentrations of omega 1 (BZ1) and omega 2 (BZ2) sites with the spinal cord containing the greatest (80%) and cerebellum the lowest (5%) concentration of omega 2 (BZ2) sites.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7870969     DOI: 10.1007/bf02244947

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  43 in total

1.  Discriminative stimulus properties of benzodiazepines, barbiturates and pharmacologically related drugs; relation to some intrinsic and anticonvulsant effects.

Authors:  F C Colpaert; L K Desmedt; P A Janssen
Journal:  Eur J Pharmacol       Date:  1976-05       Impact factor: 4.432

2.  Discriminative stimulus properties of chlordiazepoxide and zolpidem. Agonist and antagonist effects of CGS 9896 and ZK 91296.

Authors:  D J Sanger; B Zivkovic
Journal:  Neuropharmacology       Date:  1987-05       Impact factor: 5.250

3.  Benzodiazepine receptor binding in vivo with [3H]-Ro 15-1788.

Authors:  N E Goeders; M J Kuhar
Journal:  Life Sci       Date:  1985-07-29       Impact factor: 5.037

Review 4.  Molecular biology of GABAA receptors.

Authors:  R W Olsen; A J Tobin
Journal:  FASEB J       Date:  1990-03       Impact factor: 5.191

5.  Imidazopyridines as a tool for the characterization of benzodiazepine receptors: a proposal for a pharmacological classification as omega receptor subtypes.

Authors:  S Z Langer; S Arbilla
Journal:  Pharmacol Biochem Behav       Date:  1988-04       Impact factor: 3.533

6.  Midazolam cue in rats: generalization tests with anxiolytic and other drugs.

Authors:  H S Garcha; I C Rose; I P Stolerman
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

7.  Generalization between benzodiazepine- and triazolopyridazine-elicited discriminative cues.

Authors:  J F McElroy; R S Feldman
Journal:  Pharmacol Biochem Behav       Date:  1982-10       Impact factor: 3.533

8.  Investigation of the development of tolerance to the actions of zolpidem and midazolam.

Authors:  D J Sanger; B Zivkovic
Journal:  Neuropharmacology       Date:  1987-10       Impact factor: 5.250

Review 9.  Novel anxiolytics that act as partial agonists at benzodiazepine receptors.

Authors:  W Haefely; J R Martin; P Schoch
Journal:  Trends Pharmacol Sci       Date:  1990-11       Impact factor: 14.819

10.  The distribution of 13 GABAA receptor subunit mRNAs in the rat brain. II. Olfactory bulb and cerebellum.

Authors:  D J Laurie; P H Seeburg; W Wisden
Journal:  J Neurosci       Date:  1992-03       Impact factor: 6.167

View more
  7 in total

1.  Lorazepam should no longer be used as a prototypical benzodiazepine.

Authors:  S Pompéia; O F A Bueno; S Tufik
Journal:  Psychopharmacology (Berl)       Date:  2003-05-28       Impact factor: 4.530

2.  What makes lorazepam different from other benzodiazepines?

Authors:  S Pompéia; G M Manzano; S Tufik; O F A Bueno
Journal:  J Physiol       Date:  2005-12-01       Impact factor: 5.182

Review 3.  The behavioral pharmacology of zolpidem: evidence for the functional significance of α1-containing GABA(A) receptors.

Authors:  Amanda C Fitzgerald; Brittany T Wright; Scott A Heldt
Journal:  Psychopharmacology (Berl)       Date:  2014-02-22       Impact factor: 4.530

4.  Evaluation of the discriminative stimulus effects of the novel sedative-hypnotic CL 284,846.

Authors:  K E Vanover; J E Barrett
Journal:  Psychopharmacology (Berl)       Date:  1994-07       Impact factor: 4.530

5.  Zolpidem induced hyponatremia: a case report.

Authors:  Shanmuga Priya S; Britto Dl; Saravanan T
Journal:  J Clin Diagn Res       Date:  2014-09-20

6.  Contribution of alpha1 subunit-containing gamma-aminobutyric acidA (GABAA) receptors to motor-impairing effects of benzodiazepines in squirrel monkeys.

Authors:  Stephanie C Licata; Donna M Platt; James M Cook; Michael L Van Linn; James K Rowlett
Journal:  Psychopharmacology (Berl)       Date:  2008-11-25       Impact factor: 4.530

7.  Discriminative stimulus effects of alpidem, a new imidazopyridine anxiolytic.

Authors:  D J Sanger; B Zivkovic
Journal:  Psychopharmacology (Berl)       Date:  1994-01       Impact factor: 4.530

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.